PMID- 36517080
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20221222
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 15
IP  - 12
DP  - 2022 Dec 14
TI  - Treatment of induced oligometastatic disease after partial response to 
      immunochemotherapy in patient with stage IV non-small cell lung cancer and severe 
      toxicity.
LID - 10.1136/bcr-2022-252590 [doi]
LID - e252590
AB  - Treatment of induced oligometastatic disease after partial response to systemic 
      antineoplastic therapy in non-small cell lung cancer (NSCLC) remains 
      controversial. The introduction of immune checkpoint inhibitors (ICIs) has 
      revolutionised the treatment of stage IV NSCLC. While ICI combined with 
      chemotherapy (ChT) leads to longer duration of response and higher response rates 
      compared with ChT alone, it can also cause serious adverse events (AEs) resulting 
      in treatment discontinuation. In case of treatment discontinuation due to AEs 
      after partial response to systemic treatment, surgical treatment of residual 
      disease can be considered as it could lead to complete response. We present a 
      case of a patient with stage IV NSCLC who is currently alive without any signs of 
      cancer after partial response to ICI/ChT followed by surgical removal of residual 
      disease.
CI  - (c) BMJ Publishing Group Limited 2022. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Mughal, Hamza Abrar
AU  - Mughal HA
AD  - Department of Oncology and Clinical Cancer Research Center, Aalborg University 
      Hospital, Aalborg, Denmark.
FAU - Mouritzen, Mette T
AU  - Mouritzen MT
AD  - Department of Oncology and Clinical Cancer Research Center, Aalborg University 
      Hospital, Aalborg, Denmark.
AD  - Department of Clinical Medicine, Faculty of Medicine, Aalborg University, 
      Aalborg, Denmark.
FAU - Takacs-Szabo, Zsuzsanna
AU  - Takacs-Szabo Z
AD  - Department of Radiology, Aalborg University Hospital, Aalborg, Denmark.
FAU - Szejniuk, Weronika Maria
AU  - Szejniuk WM
AUID- ORCID: 0000-0001-6790-6710
AD  - Department of Oncology and Clinical Cancer Research Center, Aalborg University 
      Hospital, Aalborg, Denmark wszejniuk@gmail.com.
AD  - Department of Clinical Medicine, Faculty of Medicine, Aalborg University, 
      Aalborg, Denmark.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20221214
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - *Lung Neoplasms/pathology
MH  - Immunotherapy/adverse effects
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC9756170
OTO - NOTNLM
OT  - Cancer intervention
OT  - Lung cancer (oncology)
OT  - Surgical oncology
COIS- Competing interests: None declared.
EDAT- 2022/12/15 06:00
MHDA- 2022/12/17 06:00
PMCR- 2024/12/14
CRDT- 2022/12/14 20:52
PHST- 2024/12/14 00:00 [pmc-release]
PHST- 2022/12/14 20:52 [entrez]
PHST- 2022/12/15 06:00 [pubmed]
PHST- 2022/12/17 06:00 [medline]
AID - 15/12/e252590 [pii]
AID - bcr-2022-252590 [pii]
AID - 10.1136/bcr-2022-252590 [doi]
PST - epublish
SO  - BMJ Case Rep. 2022 Dec 14;15(12):e252590. doi: 10.1136/bcr-2022-252590.